STAR*D is a multisite, prospective, randomized, multistep clinical trial of outpatients with nonpsychotic major depressive disorder. The study compares various treatment options for those who do not attain a satisfactory response with citalopram, …

2008年2月25日 · The NIMH-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study was conducted to determine the effectiveness of different treatments for people with major depression who have not responded to initial treatment with an antidepressant. This is the largest and longest study ever conducted to evaluate depression treatment.

2004年2月1日 · STAR*D is a multisite, prospective, randomized, multistep clinical trial of outpatients with nonpsychotic major depressive disorder. The study compares various treatment options for those who do not attain a satisfactory response with citalopram, a selective serotonin reuptake inhibitor antidepressant.

Sequenced Treatment Alternatives to Relieve Depression (STAR*D) was a collaborative study on the treatment of depression, funded by the National Institute of Mental Health. Its main focus was on the treatment of depression in patients where the …

STAR*D aimed for the first time to provide solid scientific evidence regarding which next treatment steps are best for treatment-resistant depression. The results should produce clinical, administrative and economic benefits.

The STAR*D trial is the largest and most consequential antidepressant study ever conducted, with over 120 journal articles published by study investigators, innumerable citations of STAR*D’s findings by other researchers, and extensive coverage in the media, thereby giving it an oversized impact on the treatment of depression, worldwide.

2022年2月18日 · 抑郁症的序贯治疗研究（STAR*D）于2001年启动，是精神医学的里程碑之一，被视为理解真实世界临床转归的三大有效性研究之一。 STAR*D研究旨在解决抑郁症「下一步治疗」头对头数据缺乏的问题；该研究自身也证明，三分之二的患者需要这些数据。 STAR*D研究为人们理解抑郁症的现象学及病程作出了重要的贡献。 然而，该研究的设计也遭到了严厉的批评，原因在于没有充分体现出不同治疗手段之间的差异，带来了一种「怎么治都差不多」的治疗虚无 …

Relieve Depression (STAR*D) study, the largest prospective clinical trial of treatment of major depressive disorder ever conducted. It was funded by the National Institutes of Health and directed by A. John Rush, MD. WHAT WERE THE AIMS OF STAR*D? Depression, a common and debilitating condi-tion, affects approximately one in eight people

Objective: The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial is the largest open-label, pragmatic trial that has been undertaken to examine the treatment of major depressive disorder. At a cost of US$35 million over 6 years, STAR*D sought to test the effectiveness both of pharmacotherapy and of cognitive therapy, and to ...

STAR*D differs from standard RCTs in 6 key ways. The first 3 pertain to study generalizability; that is, broad inclusion criteria with few exclusion criteria, the integration of patient choice, and open-label treatment.